INTRODUCTION AND OBJECTIVES: Current evidence strongly supports the use of multiparametric magnetic resonance imaging (mpMRI) pre-biopsy in men with a suspicion of prostate cancer (PCa) based on elevated PSA. Nevertheless, concerns remain about the negative predictive value of MRI and the potential to miss significant cancers when withholding patients with a negative mpMRI from undergoing prostate biopsies.
The objective of this study is to evaluate the clinical outcomes of men with a negative mpMRI (nMRI) after at least 5-years follow-up at our institution.
METHODS: We retrospectively analysed a database of 1741 patients that received an mpMRI-scan in our institution between 2006-2013. All patients (n[297) with a negative MRI and a minimum of 5-year follow-up after this MRI were included in our study. For analysis patients were divided in to two groups: biopsy-naïve patients (group A) and patients with previous negative biopsy (group B).
Kaplan-Meier survival analysis was performed to determine 5-year csPCa and any-grade PCa diagnosis-free survival probabilities in both groups. Multivariate Cox regression analysis was performed to identify predictors of csPCa using the age, previous negative biopsies and PSA-density. A p-value of <0,05 was considered statistically significant. Both p-values were corrected for multiple testing using the Bonferroni method.
RESULTS: Of all 297 men with nMRI 138 fitted the inclusion criteria. Of these patients 60 were biopsy naïve (group A) and 78 had previous negative biopsies (groups B). The overall prevalence of clinically significant prostate cancer (csPCA) in patients with nMRI was 12% in our study.
Any-grade PCa diagnosis-free survival probability at 60 months was 91% and 97% for group A and group B respectively (log rank p[0,08). The csPCa diagnosis-free survival at 60 months was 91% for group A and 99% for group B (log rank p < 0,001).
Multivariate Cox regression showed that higher PSA-density (PSAD, ng/ml2) is an independent predictor of subsequent csPCa in men with nMRI (p < 0,05, HR 7,3). Previous negative biopsy predicts a lower risk of csPCa diagnosis probability in patients with negative MRI (p <0,05, HR 0,14).
Study limitations include the small study population and its retrospective design.
CONCLUSIONS: Our study showed that nMRI is a reliable tool to predict the absence of clinically significant PCA at 5 years, even more so in patients with previous negative biopsy. In patients without a previous biopsy and a high PSA-density, systematic biopsies should be considered, despite an nMRI.
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MP24-11 MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION BIOPSY VERSUS TRANS-PERINEAL BIOPSY IN THE SETTING OF PRIOR NEGATIVE TRANS-RECTAL PROSTATE BIOPSY: DOES MRI-US FUSION HAVE THE EDGE?
Michael Stencel*, James Kelley, Sharon Hill, Nathan Hale, Samuel Deem, Charleston, WV INTRODUCTION AND OBJECTIVES: Trans-rectal ultrasoundguided biopsy (TRUS-Bx) has been the traditional standard for diagnosing prostate cancer. However, its potential infectious complications and relatively low cancer detection have fostered development of new approaches and techniques. Patients with prior negative biopsy and persistently elevated PSA pose a management dilemma, and often undergo repeat trans-rectal biopsies. Magnetic resonance-ultrasound (MRI-US) fusion biopsy and trans-perineal systematic biopsy have shown improved cancer detection rates, yet these modalities have not been directly compared.
METHODS: After obtaining institutional review board approval, retrospective review was performed on patients with prior negative TRUSBx that had continued clinical suspicion for prostate cancer due to elevated PSA. Systematic trans-perineal prostate biopsy (TP-Bx) and MRI-US fusion guided prostate biopsy (MRI-Bx) were directly compared, with detection of clinically significant prostate cancer being the primary endpoint, and overall cancer detection as a secondary outcome.
RESULTS: 51 patients in total were reviewed, with 23 undergoing MRI-Bx and 28 with TP-Bx. Mean patient age was 68 v. 66 years (MRI-Bx v. TP-Bx) and median PSA 10 v. 7.1 ng/dL (MRI-Bx v. TP-Bx). Mean prostate volume was 72.8 v. 54.3 (MRI-Bx v. TP-Bx). Age, PSA, and prostate volume were not significantly different between the two groups. Mean number of cores sampled from the region of interest in the MRI-Bx were 5, and 23.7 cores in the systematic TP-Bx. When comparing MRI-Bx directly with TP-Bx, overall prostate cancer detection rates were 73.9% v. 42.8%, respectively (p<0.05). Clinically significant prostate cancer (Gleason score ! 7) was detected at a rate of 60.9% in the MRI-Bx and 21.4% in TP-Bx groups (p<0.05).
CONCLUSIONS: When comparing MRI-US fusion biopsy to trans-perineal biopsy in patient with previous negative prostate biopsy, MRI-US fusion appears superior in detection of both clinically significant and overall prostate cancer. Despite its lower cancer detection rates in this setting, trans-perineal biopsy may still offer a reasonable option for those with negative MRI or contraindication for MRI. METHODS: We performed a retrospective review of all men with a PI-RADS category 3 lesion on mp-MRI of the prostate between March 2012 and July 2017. Patients with previous diagnosis of prostate cancer, as well as those without post-MRI biopsy were excluded. CSC was defined as Gleason 7þ or greater than 1/3 of total cores positive for cancer. Logistic regression and chi square analyses were performed to identify RFs associated with CSC. Receiver operating characteristic (ROC) curves were generated to evaluate the predictive utility of PSAD and %Free PSA in predicting CSC.
RESULTS: A total of 368 patients were included in the cohort. On post-MRI biopsy findings (both fusion and standard transrectal if no discrete lesion noted), 220 of 368 (59.8%) were benign, 89 (16.0%) were clinically insignificant (Gleason 6, <1/3 cores), and 89 (24.2%) were clinically significant. On multivariate logistic regression analysis, decreased %freePSA (Odds ratio [OR] 1.10, p [ 0.032) and
